Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engraftis
- Development stage
- Preclinical
- Lead developer
- PKMed
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
Engraftis (PKM-02) is an innovative, locally administered regenerative therapy designed as an artificial bone marrow niche to treat poor graft function and enhance successful engraftment following hematopoietic stem cell transplantation (HSCT). Developed by PK MED, Engraftis consists of controlled-release microparticles of the small molecule thrombopoietin receptor agonist eltrombopag encapsulated within a biodegradable polymeric matrix. It is designed for direct intramedullary injection or implantation into the patient's bone marrow prior to transplantation, where it acts locally to promote stem cell homing, support healthy blood cell production, and improve transplant outcomes while minimizing systemic exposure.
- Brand names
- Engraftis
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on Engraftis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engraftis.